Physician profile
Gregory Palko
NPI 1184150518
$2,978.22
in general payments reported to CMS, 2019-2025
19 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.33 · 2023: $545 · 2024: $1,117 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,896 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,895.99 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $640.90 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $532.82 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $426.70 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Pfizer INC. | $171.91 | 2023-2025 | |
| Glaxosmithkline, LLC. | $168.40 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Intra-Sana Laboratories | $167.50 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Abbott Laboratories | $134.55 | 2023-2024 | Freestyle Libre 3, Xience Sierra |
| Merck Sharp & Dohme LLC | $127.24 | 2023-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Astellas Pharma US INC | $120.07 | 2024 | Veozah |
| Abbvie INC. | $106.24 | 2025 | |
| Exact Sciences Corporation | $82.46 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $80.19 | 2023-2024 | |
| Allergan, INC. | $73.33 | 2019 | |
| Boston Scientific Corporation | $45.60 | 2024 | Wavewriter Alpha Prime 16 |
| Neurocrine Biosciences, INC. | $29.54 | 2024 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $20.33 | 2024 | Voquezna |
| Biogen, INC. | $19.11 | 2023 | Spinraza |
| Inspire Medical Systems, INC. | $18.60 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $12.73 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Palko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.